RxDoctor Payments Data

Kimberly Adams, NP

Nurse Practitioner · Chattanooga, TNNPI 1306867031

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 49.3% of the total. 2025 is the largest year on record at $118, 3.6 times the $33 reported in 2021.

$240in general payments, 2019–2025

Across 7 payments — averaging $34.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$118
  • Acadia Pharmaceuticals Inc$38
  • Sun Pharmaceutical Industries Inc.$21
  • AbbVie$21
  • Avanir Pharmaceuticals, Inc.$16
  • Otsuka America Pharmaceutical, Inc.$14
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$240 in reported general payments places this provider in the 55th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$66,122
Medicare patients
167
Services billed
735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine38$19,356
RexultiBrexpiprazole25$16,212
Divalproex Sodium794$12,488
Duloxetine Hcl811$6,577
Trazodone Hcl995$4,189
Sertraline Hcl899$4,174
Quetiapine Fumarate783$4,053
Mirtazapine749$3,957
Olanzapine509$2,970
Aripiprazole224$2,923
Buspirone Hcl551$2,816
Ziprasidone Hcl216$2,726
Escitalopram Oxalate507$2,454
Haloperidol Decanoate39$2,284
Lorazepam304$2,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$16$19,35638 claims
Otsuka America Pharmaceutical, Inc.Rexulti$14$16,21225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →